To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Clement Chung

Abstract

Although programmed death-ligand 1 is currently the best available biomarker for first-line therapy with pembrolizumab for patients with non-small cell lung cancer and is a required companion test approved by the US Food and Drug Administration, programmed death-ligand 1 testing is an option (as a complementary test) for patients treated with nivolumab, atezolizumab, and durvalumab. Programmed death-ligand 1 expression is continuously variable and dynamic in the tumor microenvironment. Due to the complex molecular and cellular interactions involved in immune response, a single biomarker may not be sufficient to predict response to cancer immunotherapy. Integration of multiple tumor, immune response, and genomic parameters is likely to influence the future interpretation of biomarker-based treatment outcomes. This article, in a case-based format, concisely summarizes most up-to-date evidence in answering some commonly seen clinical controversies of cancer immunotherapy, in terms of (i) the predictive value of programmed death-ligand 1 as a biomarker; (ii) whether the use of steroids with checkpoint inhibitors will decrease efficacy of the latter; (iii) selection of patients for cancer immunotherapy based on immune-based response...Continue Reading

References

Aug 1, 1995·The Journal of Experimental Medicine·M F Krummel, J P Allison
May 8, 1993·International Journal of Cancer. Journal International Du Cancer·T Boon
Jan 1, 1996·British Journal of Cancer·P KorkolopoulouK C Gatter
Mar 22, 1996·Science·D R LeachJ P Allison
Oct 8, 1999·Immunity·E Gilboa
Jan 5, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jerome GalonStefan R Bornstein
May 30, 2006·Advances in Immunology·Charles G DrakeDrew M Pardoll
Jun 13, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Daniela RozkovaRadek Spisek
Nov 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephanie G DowneySteven A Rosenberg
Sep 2, 2008·Immunological Reviews·Brian T Fife, Jeffrey A Bluestone
Oct 11, 2008·Science·Kajsa WingShimon Sakaguchi
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jan 12, 2011·Annual Review of Immunology·Matthew D VeselyMark J Smyth
Mar 1, 2010·Therapeutic Advances in Medical Oncology·Sunali MehtaCristin Print
Jul 31, 2013·Immunity·Daniel S Chen, Ira Mellman
Feb 20, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ching-Yao YangPan-Chyr Yang
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Jul 11, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K AzumaI Okamoto
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Jun 4, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MassiM Mandalà
Jul 3, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Keith M KerrUNKNOWN IASLC Pathology Committee
Jul 25, 2015·Nature Reviews. Immunology·E John Wherry, Makoto Kurachi
Aug 12, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Victoria L Chiou, Mauricio Burotto
Aug 25, 2015·Aging·Le MinUrsula B Kaiser
Sep 12, 2015·Science·Eliezer M Van AllenLevi A Garraway
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Nov 22, 2015·Cancer Treatment Reviews·Xiangjiao MengJinming Yu
Mar 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Stephen HodiJedd D Wolchok
May 19, 2016·Immunity·Jonathan H EsenstenJeffrey A Bluestone
May 19, 2016·Immunity·Lindsay K Ward-KavanaghCarl F Ware
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Sep 24, 2016·Immunology·Emma Reeves, Edward James
Nov 16, 2016·Journal of Immunotherapy·Douglas B JohnsonRyan J Sullivan
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Dec 8, 2016·The Lancet Oncology·Geoffrey T GibneyMichael B Atkins
Dec 21, 2016·Nature Reviews. Clinical Oncology·Saskia LitièreJan Bogaerts
Mar 9, 2017·The Lancet Oncology·Lesley SeymourUNKNOWN RECIST working group

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
Assay

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.